MAPK3 and prostate carcinoma: To examine whether TSPAN1 is upstream of key cell signalling pathways in prostate cancer, we tested whether depletion of TSPAN1 influenced PIK3 signalling (detected using phospho-AKT) or RAS/ERK1/2 signalling (detected using phospho-ERK1/2).